For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Contract revenue | 0 | 0 | 172,000 | 257,000 |
| Research and development | 3,221,000 | 5,505,000 | 6,570,000 | 6,670,500 |
| General and administrative | 4,036,000 | 5,000,000 | 5,615,000 | 5,986,500 |
| Impairment loss | - | - | - | 928,500 |
| Total operating expenses | 7,257,000 | 10,505,000 | 12,185,000 | 13,585,500 |
| Loss from operations | -7,257,000 | -10,505,000 | -12,013,000 | -13,328,500 |
| Interest income and other, net | 68,000 | 158,000 | 218,000 | 440,750 |
| Interest expense and other, net | 725,000 | 877,000 | 943,000 | 1,258,250 |
| Net loss | -7,914,000 | -11,224,000 | -12,738,000 | -14,146,000 |
| Net loss attributable to non-controlling interest | -2,502,000 | -4,532,000 | -5,474,000 | -6,641,500 |
| Net loss attributable to rani therapeutics holdings, inc | -5,412,000 | -6,692,000 | -7,264,000 | -7,504,500 |
| Net loss per class a common share attributable to rani therapeutics holding, inc., basic | -0.12 | -0.18 | -0.22 | -0.263 |
| Net loss per class a common share attributable to rani therapeutics holding, inc., diluted | -0.12 | -0.18 | -0.22 | -0.263 |
| Weighted average number of shares outstanding, basic | 46,444,000 | 36,542,000 | 33,440,000 | 7,119 |
| Weighted average number of shares outstanding, diluted | 46,444,000 | 36,542,000 | 33,440,000 | 7,119 |
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)